These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15986013)

  • 1. Immunosuppressive treatment options in renal transplantation.
    Ciancio G; Burke GW; Jorge D; Rosen A; Miller J
    Minerva Urol Nefrol; 2005 Sep; 57(3):141-9. PubMed ID: 15986013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 3. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 5. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
    Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of cyclosporine in renal transplantation.
    Hesselink DA; Smak Gregoor PJ; Weimar W
    Transplant Proc; 2004 Mar; 36(2 Suppl):99S-106S. PubMed ID: 15041316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization.
    Smith JM; Nemeth TL; McDonald RA
    Pediatr Transplant; 2004 Oct; 8(5):445-53. PubMed ID: 15367279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.
    Charpentier B; Thervet E
    Transplant Proc; 1998 Jun; 30(4):1331-2. PubMed ID: 9636541
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunossupresive drugs in renal transplantation].
    Baczkowska T; Durlik M
    Pol Arch Med Wewn; 2004 Oct; 112 Spec No():99-120. PubMed ID: 15669207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts and perspectives of immunosuppression in organ transplantation.
    Scherer MN; Banas B; Mantouvalou K; Schnitzbauer A; Obed A; Krämer BK; Schlitt HJ
    Langenbecks Arch Surg; 2007 Sep; 392(5):511-23. PubMed ID: 17450373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus in transplant rejection.
    Rath T
    Expert Opin Pharmacother; 2013 Jan; 14(1):115-22. PubMed ID: 23228138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclizumab in live donor renal transplantation.
    Iverson AJ; Vick SC; Sarnacki CT; Wright FH
    Transplant Proc; 2000 Jun; 32(4):790-2. PubMed ID: 10856587
    [No Abstract]   [Full Text] [Related]  

  • 15. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.
    Vincenti F; Nashan B; Light S
    Transplant Proc; 1998 Aug; 30(5):2155-8. PubMed ID: 9723424
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A; Grego K; Bren AF
    Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
    Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunosuppression for kidney transplant recipients: current strategies].
    Alberú J; Urrea EM
    Rev Invest Clin; 2005; 57(2):213-24. PubMed ID: 16524061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.